| Active substance | somatotropin |
| Holder | Novo Nordisk Pharma |
| Status | on hold |
| Indication | growth failure in children with achondroplasia/hypochondroplasia |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 04/03/2024 |
Norditropin®
Last updated on 10/09/2024